Pliant Therapeutics Pauses Lead Product Mid-Stage Trial In Patients With Stiff Lung Tissues
1. Pliant paused enrollment in BEACON-IPF trial after DSMB's recommendations. 2. Current participants will remain in the trial during data review. 3. Topline data from another trial shows bexotegrast reduced lung collagen. 4. PLRX stock fell 64.10% in premarket trading after the announcement. 5. Positive past results from INTEGRIS-PSC trial indicate treatment efficacy.